State-of-the-art genetics panel optimizes kidney disease treatment: Linnea M. Baudhuin, Ph.D., and Emily K. Thoreson, M.S., CGC


Test in Focus

Genetic factors play a role in at least 10% of adult cases of kidney disease and up to 70% of cases in children. In this "Test in Focus" episode of the "Answers From the Lab" podcast, Linnea M. Baudhuin, Ph.D., and Emily K. Thoreson, M.S., CGC, explain how Mayo Clinic Laboratories renal genetics testing provides comprehensive and accurate results for optimal patient care.

"Our tests are among the most comprehensive diagnostic tests available. They utilize next generation sequencing for maximum depth of coverage and the highest possible detection rates across 302 genes, including technically challenging genes," Dr. Baudhin says.

The testing can identify potential underlying genetic causes of kidney disease and the specific type of kidney disease a patient has. "The results can then be used to guide treatment, inform prognosis and assess family members' risk," Thoreson says.

Unlike competitors' screening tests, Mayo Clinic Laboratories' panels are diagnostic. "You can trust them to identify an actual medical condition," Dr. Baudhin says. "Screening tests require clinical confirmation. The actual implications of the results are harder to understand."

Listen to learn more about Mayo Clinic Laboratories' renal genetics panel.

Note: Podcasts will not playback on Internet Explorer. Please use an alternative web browser, or listen from your mobile device on a preferred listening app.

The latest from Test in Focus

Barbara J. Toman (@barbaratoman)

Barbara J. Toman

Barbara J. Toman is a Senior Communications Specialist at Mayo Clinic Laboratories. She is also the science writer for Mayo’s Neurosciences Update newsletter, which helps referring physicians to stay informed about Mayo’s treatment and research. Barbara has worked at Mayo Clinic since 2007. She enjoys international travel and cooking.